Hosted on MSN4d
Celltrion’s Avtozma receives FDA approval for multiple conditions
The FDA's approval is grounded in an evidence totality and comprehensive data package, which includes outcomes from a study.
infectiousdiseaseadvisor.com2d
FDA Approves Tocilizumab Biosimilar Avtozma
The FDA has approved Avtozma® (tocilizumab-anoh), a biosimilar to Actemra®, in both intravenous and subcutaneous formulations.
centerforbiosimilars7d
FDA Approves Celltrion's Avtozma as Third Tocilizumab Biosimilar
The FDA approved Avtozma, a tocilizumab biosimilar developed by Celltrion, for the treatment of several rheumatic conditions.
Pharmabiz6d
Celltrion’s Avtozma, a biosimilar to Actemra receives US FDA approval to treat RA, GCA, pJIA, sJIA and Covid-19
Jersey City, New Jersey Saturday, February 1, 2025, 16:00 Hrs [IST] ...
Hosted on MSN8d
Celltrion gets U.S. FDA approval for new biosimilar for autoimmune disease treatment
Celltrion Inc., a major South Korean biopharmaceutical firm, said Friday its new biosimilar for an autoimmune disease treatment has received approval from the U.S. Food and Drug Administration (FDA).
MedPage Today4d
Serious Chocolate Recall; Boy Dies in Hyperbaric Chamber; Trans Care Cancellations
NYU Langone Health in New York City reportedly cancelled the appointments of two transgender children scheduled to receive ...
Medscape4d
FDA Approves Third Tocilizumab Biosimilar
The biosimilar will be available in both subcutaneous and intravenous formulations and has nearly all the same indications as ...
The Pharma Letter4d
FDA approves Celltrion's Avtozma, a biosimilar to Actemra
The US Food and Drug Administration (FDA) has approved Avtozma (CT-P47, tocilizumab-anoh) in both an intravenous (IV) and ...
Managed Healthcare Executive4d
FDA Approves Third Biosimilar of Actemra
The new biosimilar, Celltrion’s Avtozma, was approved in both IV and subcutaneous forms to treat inflammatory conditions such as arthritis.
The American Journal of Managed Care7d
FDA Approves Celltrion’s Tocilizumab-anoh, Biosimilar to Actemra
Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, ...
Monthly Prescribing Reference8d
FDA Approves Tocilizumab Biosimilar Avtozma
The Food and Drug Administration (FDA) has approved Avtozma ® (tocilizumab-anoh), a biosimilar to Actemra ® (tocilizumab), in both intravenous (IV) and subcutaneous (SC) formulations.